Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 3 | BES2002 | Next issue

21st Joint Meeting of the British Endocrine Societies

Symposia

Differentiated Thyroid Cancer

ea0003s18 | Differentiated Thyroid Cancer | BES2002

Initiating oncogenic events in thyroid follicular cells: Impact on chromosomal instability and disease progression

Fagin J

Recent studies support a causal relationship between radiation, formation of RET/PTC rearrangements, and development of papillary carcinomas. The evidence that RET/PTC rearrangements result directly from radiation-induced DNA damage is compelling, and further substantiated by evidence that predisposition to radiation-induced intrachromosomal inversions involving the RET gene may be favored by the three-dimensional organization of human chromosome 10 during interphase. Thus, il...

ea0003s19 | Differentiated Thyroid Cancer | BES2002

Improving the utility of fine needle aspiration biopsy of thyroid tumours

Haugen B

Fine needle aspiration biopsy (FNAB) has become the mainstay of thyroid nodule evaluation. While the overall accuracy of FNAB is excellent, an indeterminate or suspicious biopsy can pose a diagnostic and management dilemma. Fortunately, only 20-25% of indeterminate nodules are ultimately found to be malignant. Unfortunately, approximately 75-80% of patients undergo a surgical procedure that may have not been necessary. Recent advances in molecular diagnostics such as immunocyt...

ea0003s20 | Differentiated Thyroid Cancer | BES2002

Differentiated Thyroid Cancer (DTC): Treatment Outcomes

Mazzaferri E

Outcomes with DTC measured in terms of cancer-specific mortality, tumor recurrence and disease-free survival rates give different views of the efficacy of treatment. In our cohort of 1528 patients (median age 34 yr, range 5-91 yr) after a median follow-up of 16.6 yr, 40-yr cancer-specific mortality was 8% and recurrence rate was 37%. A delay in treatment of 12 months or more significantly increased the 40-yr cancer-specific mortality (6.6% vs 13.5%, P=0.002). Treatment variabl...

ea0003s21 | Differentiated Thyroid Cancer | BES2002

UK thyroid cancer guidelines

Franklyn J

Thyroid cancer is the commonest endocrine malignancy but there is much debate about the role of specific treatment modalities, including the extent of surgery, post-operative ablation with iodine-131, need for TSH-suppressive doses of thyroxine, role of serum thyroglobulin measurements and imaging during follow-up. Recent data have suggested poorer outcome for thyroid cancer in the UK than other countries and recent audits have highlighted shortcomings in patient management. T...